Cargando…
Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome
We here report on a 74-year-old man diagnosed with a pT3cN0 BRAF-mutated and mismatch repair-deficient adenocarcinoma in the colon ascendens and 3 liver metastases. After hemicolectomy, the patient received treatment with the PD-1 inhibitor pembrolizumab. Three weeks later (on day 22), laboratory te...
Autores principales: | Giglio, Daniel, Berntsson, Henrik, Fred, Åsa, Ny, Lars |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670383/ https://www.ncbi.nlm.nih.gov/pubmed/33250739 http://dx.doi.org/10.1159/000510740 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020) -
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021) -
Inflammatory myopathy with myasthenia gravis: Thymoma association and polymyositis pathology
por: Uchio, Naohiro, et al.
Publicado: (2018) -
Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
por: Takamatsu, Koutaro, et al.
Publicado: (2018) -
Myasthenia Gravis as an Immune-Mediated Side Effect of Checkpoint Inhibitors
por: Heleno, Caio T, et al.
Publicado: (2021)